The non-specific melanocortin peptide agonist setmelanotide, which acts via the MC4R to inhibit food intake and produce weight loss, has been approved by the FDA for the treatment of proopiomelanocortin deficiency, leptin receptor deficiency and BardetBiedl syndrome
Real-world Response Timeline across BPC-157 Injectable Protocols Days 1 to 5: Most users reported little to no change, while some noted mild injection-site redness
Real Patient Case Studies Case Study #1: Executive Recovery and Body Recomposition Patient: 47-year-old male tech executive Chief Complaints: Poor recovery from workouts, increasing abdominal fat despite consistent exercise, declining sleep quality, mental fog Baseline Labs: IGF-1: 142 ng/mL (low for age) Testosterone: 387 ng/dL (low-normal) Body fat: 26% (DEXA) Visceral fat area: 187 cm (elevated risk) hs-CRP: 3.2 mg/L (elevated inflammation) Treatment Protocol: Weeks 1-4: Optimize testosterone to 700+ ng/dL using testosterone cypionate, address vitamin D deficiency (was 24 ng/mL) Weeks 5-20: Add sermorelin 300 mcg nightly, 6 days/week Weeks 21-32: Add tesamorelin 2 mg daily to target stubborn visceral fat 32-Week Results: IGF-1: 267 ng/mL (+89%) Body fat: 18.5% (-7.5 percentage points) Lean mass: +6.8 kg gained Visceral fat area: 98 cm (-48% reduction) hs-CRP: 0.8 mg/L (normalized) Sleep: Improved from 5.5 to 7.2 hours average, with 23% increase in deep sleep (Whoop tracking) Patient Report: The combination of testosterone optimization and peptides was transformative
For testosterone cypionate, the ester attached is the cypionate ester, while for testosterone enanthate, it's the enanthate ester
